Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.

NCT07213817 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT07213817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07213817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 5, 2025
Completion date
October 30, 2028
Enrollment
114 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic solid tumor